Myopia is more than needing glasses to see the board.
When a child’s eyesight progressively worsens year after year, every diopter of increased myopia raises their lifetime risk of serious eye disease. Standard single-vision glasses correct vision today, but they do nothing to slow what’s happening tomorrow.
Stellest® lenses are different. They simultaneously correct your child’s vision and send a biological signal to slow the eye’s elongation — the root cause of myopia progression.
CLINICAL EVIDENCE
Proven Results in Real Children
Stellest® lenses are backed by a prospective, randomized, double-masked, multicenter clinical trial — and 5-year follow-up data published in peer-reviewed journals.
*Results from FDA prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years. Comparison to single vision spectacle lenses. Li X, et al. Eye and Vision. 2025;12(1):10.

Why Choose Stellest®
Stellest® lenses fit seamlessly into your child’s everyday life — from classroom to playground — without any extra steps or compromise.
Looks & feels like normal glasses
The lenslets are nearly invisible. Other children and adults cannot tell they’re myopia-control lenses — just stylish, everyday eyewear.
School-ready sharp vision
The clear central zone ensures crisp distance and near vision for reading, whiteboards, and screens — no visual disruption to learning.
Active lifestyle-friendly
From sport to play, Stellest® lenses are worn just like regular glasses. No insertion, no hygiene protocols, no age restrictions on activity.
First FDA-authorized for myopia
The only spectacle lens to receive FDA market authorization for slowing myopia progression — backed by the most rigorous standard of clinical evidence in the U.S.
Most effective in younger children
Children aged 6–8 showed the greatest benefit, with over 1.00D less myopia and 0.37mm less axial elongation over two years compared to single-vision wearers.
Protects long-term eye health
Each diopter less of myopia at adulthood means significantly lower lifetime risk of glaucoma, cataracts, retinal detachment, and myopic maculopathy.

